Fingers xed
9 months ago
Author summary ( from mouse study )
Antiviral agents are highly important for the management of COVID-19. New antivirals are needed, because available drugs have drawbacks that limit their use and are threatened by drug resistance. This study demonstrates that the small molecule drug BIT225 is an inhibitor of an important viral ion channel (E protein). E protein is required for virus replication and is involved in eliciting inflammatory response to infection. Exacerbated inflammation is a hallmark of severe COVID-19 in mice and in humans. In a mouse model of severe SARS-CoV-2 infection, BIT225 treatment starting before or 24 hours after infection could protect all treated mice from developing disease, from experiencing weight loss and from death (100%, n = 17), while all untreated mice developed severe disease, started to lose body weight from Day 3 onwards and died within 9 days after infection. BIT225 treatment was associated with potent suppression of virus load, and reduced inflammation markers, consistent with effective clearance of the virus. These results are remarkable for the high efficacy achieved with a new mechanism of action. BIT225 is a clinical stage drug candidate with an established human safety profile. These results support clinical evaluation of BIT225 for the treatment of human SARS-CoV-2 infection.
BIT225 has previously shown antiviral activity against both HIV-1 and HCV in the clinic, as well as potential to reverse adverse viral-induced immunopathogenesis [8,9,37–40]. BIT225 is currently being evaluated in phase 2 clinical studies for its potential to reduce HIV-1 replicationAnd this is the best BIT ( pun lol ) These results indicate selective inhibition of E protein ion channel activity by BIT225 and the ability of BIT225 to fully suppress E protein ion channel current.
Now that means it don't replicate , and of course dies .
I am with you now BMD , that hunch on HIV is getting bigger and bigger .
Fingers xed
9 months ago
Covid Cure coming , this journal shows it cured mice in trials , read this Journal and you will find the compound cured mice .
https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1011328#sec002
Reading the paper on the mice trials , it feels like a cure on mice ?
Yes which is why we are doing the trial in humans. The mouse data is spectacularly good. Let’s hope it’s as good in people!
Dr Michelle Miller | CEO & Managing Director | Biotron Limited (ASX:BIT)
Suite 3.3, 56 Delhi Rd, North Ryde NSW 2113, Australia
misiu143
6 years ago
Thank you , if that will happen it will be great . ( BO or partnership )
So far I don’t see a cure for hiv here and for now , but if there will be reduction of virus in cellular reservoirs it will be a good beginning ,
Obviously they think similar way since they keeping patients still on HAART after TIB225 is stopped 12 weeks later .,,
I am following this carefully since I became an investor here !!
Dougster
6 years ago
(BITRF BiotronLTD) NEW ISSUE ANNOUNCEMENT 25 October 2018
In accordance with Listing Rule 3.10, I attach an Appendix 3B - New Issue Announcement,
Application for Quotation of Additional Securities.
This new issue of fully paid ordinary shares is from the exercise by the Company’s Chairman, Mr
Michael Hoy, of 1,246,372 30 November $0.06 listed options.
Yours sincerely
Peter J. Nightingale
Company Secretary
The Manager Companies
ASX Limited
20 Bridge Street
SYDNEY NSW 2000
Stockfun1
6 years ago
Bloomberg
Markets
How an HIV Trial Triggered a 667% Jump in Australian Penny Stock
By Divya Balji
October 3, 2018, 1:27 AM EDT
The name is Biotron Ltd., and before its five-day 667 percent rally, it had a share price of just 2 Australian cents.
The Sydney-based drug company with just five full-time employees last week announced the “successful” outcome of a phase-two trial of BIT225 HIV-1 drug and retail investors have been lapping it up. The company said its therapy suppressed the HIV virus more than current antiretrovirals.
“The data shows there are significant immunological benefits in patients receiving antiretroviral drugs with 200 mg BIT225 compared to antiretroviral drugs plus placebo,” Biotron said in a statement.
The share price jumped 11 percent the day before the announcement and then another 105 percent after the trial results were released. Since then, it’s surged more than 50 percent each day, with the stock climbing to about A$0.14 today.
It’s no surprise that penny stocks can make big moves when news is announced. Biotron’s rally in the past five days has increased its market value to A$70.3 million (about $44 million) and made it Australia’s 11th biggest gainer for the year. BidEnergy Ltd., another penny stock, is the top performer, having surged 567 percent this year.
Biotron plans to present more detailed data at scientific conferences later this year, the company said in its Sept. 28 statement.
Michelle Miller, the company’s managing director and a former scientist at Johnson & Johnson, said she’d been watching her stock price soar.
“The Australian stock market is always an interesting place,” she said. “Folks tend to over-react to bad news and then when there’s good news they react accordingly, but not always.”
— With assistance by Nicole Tang